PMID: 2123984Aug 1, 1990Paper

Animal models of parkinsonism

Pharmacology & Toxicology
S Kaakkola, H Teräväinen

Abstract

The discovery of profound dopamine depletion of basal ganglia in patients with Parkinson's disease and the development of antiparkinsonian drug therapy were largely based on animal models. The behavioural changes caused by cholinergic drugs, reserpine and related agents, and unselective neuronal lesions were the first widely used animal models for Parkinson's disease. The crucial breakthrough was the observation of the circling behaviour in rodents after unilateral intranigral injection of 6-hydroxydopamine. This Ungerstedt model still is one of the basic animal models of Parkinson's disease. It is suitable for the screening of new potential antiparkinsonian agents with the classic spectrum. The parkinsonism induced by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse and the monkey is the latest and the best animal model for Parkinson's disease. Especially when given to the monkey, MPTP causes biochemical, behavioural and neuropathological changes which largely mimick those of Parkinson's disease in man. The MPTP-induced parkinsonism in the monkey can be used for the study of the neurobiology and new forms of drugs therapy of Parkinson's disease. However, because the MPTP monkey model is expensive...Continue Reading

References

Jan 1, 1979·Pharmacology & Therapeutics. Part B: General & Systematic Pharmacology·H R Bürki
Apr 1, 1978·Pharmacology, Biochemistry, and Behavior·T Ljungberg, U Ungerstedt
Jun 1, 1976·Journal of the Neurological Sciences·J C PéchadreL J Poirier
Jan 1, 1975·Biochemical Pharmacology·C Sachs, G Jonsson
Feb 1, 1990·Journal of Neurology, Neurosurgery, and Psychiatry·N Quinn
Nov 16, 1989·The New England Journal of Medicine·UNKNOWN Parkinson Study Group
Aug 14, 1989·Brain Research·D A PereseK S Bankiewicz
Jun 1, 1989·Journal of Neurology, Neurosurgery, and Psychiatry·O Lindvall
Jan 1, 1989·Acta Neurologica Scandinavica. Supplementum·J W Tetrud, J W Langston
Oct 1, 1989·Annals of Neurology·D SchermanY Agid
Aug 1, 1987·The Journal of Pharmacy and Pharmacology·D R CooperC D Marsden
Feb 23, 1987·Life Sciences·W J NicklasR E Heikkila
Aug 1, 1987·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·A R CrossmanM A Sambrook
Aug 1, 1987·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·R E Heikkila, P K Sonsalla
Mar 1, 1986·Clinical Endocrinology·J P O'HareR J Corrall
May 16, 1985·Biochemical and Biophysical Research Communications·K ChibaN Castagnoli
Jan 1, 1971·Acta Physiologica Scandinavica. Supplementum·U Ungerstedt
Jan 1, 1971·Acta Physiologica Scandinavica. Supplementum·U Ungerstedt
Mar 1, 1966·Brain : a Journal of Neurology·L J PoirierS Carabin
Jan 1, 1966·Acta Pharmacologica Et Toxicologica·N E AndénK Larsson
Nov 13, 1984·European Journal of Pharmacology·J A Javitch, S H Snyder

❮ Previous
Next ❯

Citations

Mar 14, 1998·Biological Trace Element Research·A TakedaS Okada
Feb 5, 2003·Neurotoxicology·Analía BortolozziAna María Evangelista de Duffard
Apr 30, 1998·Progress in Neurobiology·A Richter, W Löscher
Sep 7, 2000·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·T ArakiY Itoyama
Jul 30, 1999·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·T ArakiY Itoyama
Dec 19, 2012·Indian Journal of Pharmacology·M H ShalavadiA Ramkishan
Dec 18, 2001·Movement Disorders : Official Journal of the Movement Disorder Society·R E YeeJ R Barrio
Jan 26, 2007·Pharmacology, Biochemistry, and Behavior·José L Bata-GarcíaJosé L Góngora-Alfaro
Aug 28, 2007·The Journal of Comparative Neurology·Gilmor I KeshetHelen M Blau
Jul 18, 2009·Neuroscience and Biobehavioral Reviews·Wolfgang Löscher
May 1, 2001·Current Protocols in Toxicology·T M Burbacher, K S Grant
Apr 29, 2004·Nature Neuroscience·Laurence H Tecott, Eric J Nestler
Mar 27, 2001·Phytotherapy Research : PTR·C P Bopaiah, N Pradhan
Oct 13, 2004·Phytotherapy Research : PTR·Bala V ManyamTheodore A Hare

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Basal ganglia in Parkinson's disease (MDS)

The basal ganglia is comprised of the neostriatum, the external and internal pallidal segments, the subthalamic nucleus, the substantia nigra pars reticulata, and the pars compacta of the substantia nigra. The basal ganglia circuitry is responsible for the correct execution of voluntary movements and is implicated in Parkinson's disease. Here is the latest research investigating the basal ganglia in Parkinson's disease.